NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
SIX · ROP.SW · CHF
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Roche Holding AG’s forward annual dividend is CHF 9.80 per share, paid annual. The forward yield is 2.44% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Roche Holding AG’s next earnings report is currently expected on Jan 28, 2027, with estimated earnings per share of CHF 9.62. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Roche Holding AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Roche Holding AG is a prominent global entity primarily active in the pharmaceutical and diagnostics industries. Its extensive operations encompass numerous countries, including key markets such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside a broader international presence. The company's pharmaceutical division is dedicated to developing and marketing a diverse range of medicinal products. These treatments target various therapeutic areas like oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory conditions. Additionally, their portfolio addresses specific ailments such as anemia, cancer, dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation. In the diagnostics sector, Roche supplies advanced in-vitro tests utilized for detecting and monitoring a wide array of diseases, including cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. They also provide crucial diagnostic instruments and reagents to healthcare facilities. Furthermore, Roche is engaged in a research partnership with Synlogic, Inc., focused on identifying a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). This well-established organization, founded in 1896, maintains its corporate headquarters in Basel, Switzerland.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2023 | Feb 1, 2024 | CHF 8.47-0.12% vs estimate | CHF 29.31B+0.16% vs estimate |
|---|
| Q2 2023 | Oct 19, 2023 | CHF 10.10-2.88% vs estimate | CHF 29.78B-1.71% vs estimate |
|---|
| Q2 2022 | Jul 21, 2022 | CHF 11.76+6.72% vs estimate | CHF 32.30B+0.5% vs estimate |
|---|
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
CHF 132.30+CHF 3.08 (+2.38%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 1.53% below the high.
£130.52+£2.88 (+2.26%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 17.04% below the high.
$460.73+$8.90 (+1.97%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
$165.61+$6.41 (+4.03%)
Gilead Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
